Roche Group member Genentech has expanded the exclusive strategic partnership agreement with Bicycle Therapeutics by exercising its second option to commence a new programme. 

The initial agreement was signed in February 2020 for discovering, developing and marketing new immuno-oncology therapies based on Bicycle’s bicyclic peptide technology.

Under the deal, the companies are working on discovering and conducting pre-clinical development of new immunotherapies based on Bicycle technology against various targets. 

As per the 2020 agreement, Genentech received two partnership expansion options, each of which offered the company the right to include one further programme in the partnership for a payment of $10m to Bicycle. 

Genentech exercised its first expansion option in October last year and now exercised the second option, resulting in further payment of $10m. 

The agreement is exclusive of the compounds in the oncology pipeline of Bicycle, including its immuno-oncology candidates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bicycle Therapeutics CEO Kevin Lee said: “We are pleased both with the ongoing progress in our collaboration with the preeminent immuno-oncology team at Genentech and that Genentech has once again elected to exercise an option to add a new programme. 

“This represents the second expansion option exercised by Genentech under the terms of our collaboration agreement, and we believe this highlights the potential of Bicycles across a wide range of targets.”

The companies will continue the partnership for developing potential new cancer therapies based on Bicycle technology. 

A biotechnology company, Bicycle has a differentiated class of therapies based on its bicyclic peptide technology.

In September last year, Genentech and Adaptimmune Therapeutics entered a strategic partnership and licence agreement for developing and marketing allogeneic cell therapies for treating multiple cancer indications.